CELZ Completes Enrollment and Treatment Across Entire ADAPT Trial, Advancing Olastrocel Toward RMAT and Phase 3
CELZ sits 95% above its 52-week low of $0.62 on light trading volume (0.1× avg).
Summary
Creative Medical Technology has completed enrollment and treatment across all cohorts of its FDA-cleared ADAPT trial for CELZ-201/Olastrocel, including the opioid expansion cohort. This marks a transition from active enrollment to follow-up, data maturation, and regulatory planning. The company expects ADAPT-related clinical execution costs to decrease meaningfully, which should preserve capital and extend its operating runway into 2027. Management is now preparing for RMAT evaluation and Phase 3 discussions with the FDA for a broader chronic lower back pain indication. This follows the June 22 FDA clearance to expand the trial and builds on positive interim 180-day data showing significant improvements in functional disability and pain.
At the time of this announcement, CELZ was trading at $1.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $0.62 to $6.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.